Kodiak’s tarcocimab tedromer (Zenkuda) delivered positive top-line results in the Phase 3 Glow2 trial for diabetic retinopathy, triggering plans for an accelerated, multi-indication BLA submission. The readout showed a higher proportion of patients achieving at least a two-step improvement in DR severity score versus sham, reshaping the company’s late-stage expectations after prior setbacks.